EpicentRx Inc., a drug and device company with cancer and inflammatory disease-targeted platforms, announced on Wednesday that it has completed patient enrolment in the first cohort of a Phase one trial called BETA PRIME for its TGF-beta trap-enhanced cancer targeting adenovirus.

The study has enrolled three subjects in the first cohort and is assessing the safety, tolerability, optimal dose level and immunogenicity for single and multiple doses of AdAPT-001 both alone and in combination with a checkpoint inhibitor when administered to advanced cancer patients. The AdAPT-001 Phase 1 multi-centre clinical trial is being carried out in three parts, commencing with a single dose escalation that is followed by an expansion cohort at the highest tolerable dose prior to combination with a checkpoint inhibitor.

Dr Tony R Reid, EpicentRx chief executive officer, said, 'The completion of enrolment in cohort 1 of the BETA PRIME trial is the first step for EpicentRx on its journey to bring a first-in-class treatment to the millions of patients in America and ultimately around the world that are afflicted with resistant cancer. To date, we have seen no serious adverse events in the trial. To defeat cancer what is needed are therapeutic agents like AdAPT-001 that are not only as genetically sophisticated as the tumour itself but also that are minimally toxic.'